Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
Hypoglycemic effect
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "Hypoglycemic effect" in MCE Product Catalog:
4
Target:
Research Areas:
Chlorpropamide is an oral hypoglycemic agent that can influence acetaldehyde metabolism in mice and has a potentiating effect on antidiuretic hormone .
1
1 Cited Publications
Cat. No.: HY-P4860
CAS No.: 1802086-30-1
Research Areas:
Synonyms: B28Asp; B28-Asp-insulin; INA-X 14; Insulin X 14
Target:
Research Areas:
Cat. No.: HY-N0500
CAS No.: 130567-83-8
Category:
Triterpenes Terpenoids Cucurbitaceae Metabolic Disease Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Disease Research Fields Sweeteners Food Research
Target:
Cat. No.: HY-N7377
CAS No.: 17851-53-5
Target:
Cat. No.: HY-128740
CAS No.: 31635-99-1
Target:
Cat. No.: HY-172811
CAS No.: 2969158-02-7
Target:
Research Areas:
DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S stimulates insulin secretion and shows hypoglycemic effects. DA-302168S decreases food intake. DA-302168S mainly activates GLP-1R of monkeys and humans, and exhibits little excitatory effect on GLP-1R of rats, mice, and dogs. DA-302168S can be used for type 2 diabetes and obesity study .
Cat. No.: HY-162136
CAS No.: 1821647-46-4
Target:
Research Areas:
GPR40 agonist 7 (Compound 1) is an orally active G protein-coupled receptor 40 (GPR40) agonist. GPR40 agonist 7 can significantly increase insulin and GLP-1 secretion, and has a hypoglycemic effect in vivo with an ED50 of 0.58 mg/kg
Cat. No.: HY-150723
CAS No.: 2857098-72-5
Target:
Research Areas:
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research .
Cat. No.: HY-144713
CAS No.: 2848581-86-0
Target:
Research Areas:
PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.
Cat. No.: HY-144716
CAS No.: 2848581-83-7
Target:
Research Areas:
PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.
Cat. No.: HY-144718
CAS No.: 2848581-85-9
Target:
Research Areas:
PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
Cat. No.: HY-N20264
Synonyms: Gamazumi extract
Category:
Target:
Cat. No.: HY-180784
Target:
Research Areas:
Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, SGLT1, and GLUT2. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes .
Cat. No.: HY-W207669
CAS No.: 22587-11-7
Target:
Research Areas:
Centpiperalone is an orally active hypoglycemic agent. Centpiperalone mainly achieves its hypoglycemic effect by promoting the release of insulin by pancreatic β cells. Centpiperalone can effectively lower blood sugar levels in both normal and diabetic animals. Centpiperalone can be used in research on diabetes .
Cat. No.: HY-183205
CAS No.: 1628744-37-5
Target:
Research Areas:
SSTR5 antagonist 7 is an orally active SSTR5 antagonist, with an IC50 of 6.2 nM against hSSTR5 and an IC50 of 25 nM against mouse-derived SSTR5. SSTR5 antagonist 7 exerts a sustained hypoglycemic effect. SSTR5 antagonist 7 can be used for the research of diabetes .
Cat. No.: HY-182280
Target:
Research Areas:
BDM71230 is an orally active inducer of insulin-degrading enzyme (IDE), with an EC50 of 1.9 μM against human IDE. BDM71230 binds to the interface of IDE dimers and enhances the catalytic activity of IDE via steric effects. BDM71230 can potentiate the hydrolytic effect of IDE on insulin and slightly attenuate the hypoglycemic effect of insulin. BDM71230 serves as a pharmacological tool for investigating IDE function and is applicable to studies related to glucose intolerance .
Research Areas:
Oxophenarsine hydrochloride is an anti-syphilitic agent, and also has non-classical applications including treating chronic discoid lupus erythematosus, inhibiting HIV-1 protein synthesis, and prolonging the duration of insulin action . Oxophenarsine hydrochloride forms an unstable insulin complex via sulfhydryl groups or free amino groups, thereby prolonging the hypoglycemic effect of insulin. Oxophenarsine hydrochloride inhibits HIV-1-specific protein synthesis and virus production .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
